Analysts Optimistic About Acuity Brands: Margin Expansion And Supply Chain Improvements To Drive Growth

Oppenheimer analyst Christopher Glynn reiterated an Outperform rating on Acuity Brands, Inc. (NYSE:AYI) with a price target of $210. The analyst noted…
  • Oppenheimer analyst Christopher Glynn reiterated an Outperform rating on Acuity Brands, Inc. (NYSE:AYI) with a price target of $210.
  • The analyst noted that the company would gain from significant structural supply chain improvements, supporting its margins, which will drive further the second half of the fiscal year.
  • Strategic pricing and runway on favorable input cost trends are also expected to reinforce further clarity for gross margins. 
  • The company will also benefit from improving supplier network productivity and data utilization into demand and production, retaining a “meaningful process improvement runway.”
  • Volumes into distribution for reselling will continue to see solid growth and sell-through, with a healthy share traction in channel inventory continuing. 
  • However, quickly normalizing lead times may contribute substantially to slowing orders, resulting in some project-dedicated inventory work-down in the channel.
  • The analyst revised FY23E EPS to $13.50 from $13.80 and for FY24 to $11.60 from $14.95.
  • Price Action: AYI shares are trading lower by 0.09% at $158.32 on the last check Tuesday.
Total
0
Shares
Related Posts
Read More

Acrivon Therapeutics Presents Data Demonstrating Capabilities Of Its AP3 Platform And ACR-368 OncoSignature Assay For Patient Responder Identification At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction

ACRV